Compare BNC & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNC | XOMA |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 308.6M |
| IPO Year | N/A | N/A |
| Metric | BNC | XOMA |
|---|---|---|
| Price | $2.84 | $30.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | ★ 230.7K | 99.5K |
| Earning Date | 03-16-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.95 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | ★ $0.22 | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.93 | $18.40 |
| 52 Week High | $31.62 | $39.92 |
| Indicator | BNC | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 65.21 |
| Support Level | N/A | $23.92 |
| Resistance Level | $4.14 | $30.79 |
| Average True Range (ATR) | 0.26 | 1.49 |
| MACD | 0.01 | 0.32 |
| Stochastic Oscillator | 1.16 | 74.74 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.